Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy C4 Therapeutics stock

Own C4 Therapeutics stock in just a few minutes.

C4 Therapeutics, Inc is an other business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in C4 Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CCCC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

C4 Therapeutics share price

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$19.00 - $48.98
50-day moving average $36.05
200-day moving average $34.57
Wall St. target price$56.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy C4 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

C4 Therapeutics financials

Revenue TTM $33.2 million
Gross profit TTM $33.2 million
Return on assets TTM -14.58%
Return on equity TTM -47.41%
Profit margin -199.83%
Book value N/A
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting C4 Therapeutics shares

There are currently 3.0 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 19.1% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.

C4 Therapeutics's "short interest ratio" (SIR)

C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 461632.19284603). C4 Therapeutics's SIR currently stands at 6.43. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 6430 shares are currently held short.

To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.

However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0936% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 94 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.

Find out more about how you can short C4 Therapeutics stock.

C4 Therapeutics share dividends

We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.

C4 Therapeutics overview

C4 Therapeutics, Inc. , a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site